Last reviewed · How we verify

PO Acetaminophen

Corewell Health West · FDA-approved active Small molecule Quality 5/100

PO Acetaminophen, marketed by Corewell Health West, is a well-established over-the-counter pain reliever and fever reducer. The key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk lies in the competitive landscape, where multiple generic and branded alternatives are already available.

At a glance

Generic namePO Acetaminophen
Also known asTylenol, tylenol, Acetaminophen Elixir
SponsorCorewell Health West
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: